Cargando…
Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges
No disease-modifying therapies (DMT) for neurodegenerative diseases (NDs) have been established, particularly for Alzheimer's disease (AD) and Parkinson's disease (PD). It is unclear why candidate drugs that successfully demonstrate therapeutic effects in animal models fail to show disease...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Neurological Association
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063862/ https://www.ncbi.nlm.nih.gov/pubmed/27819412 http://dx.doi.org/10.3988/jcn.2016.12.4.381 |
_version_ | 1782460048762470400 |
---|---|
author | Kim, Dana Kim, Young-Sam Shin, Dong Wun Park, Chang-Shin Kang, Ju-Hee |
author_facet | Kim, Dana Kim, Young-Sam Shin, Dong Wun Park, Chang-Shin Kang, Ju-Hee |
author_sort | Kim, Dana |
collection | PubMed |
description | No disease-modifying therapies (DMT) for neurodegenerative diseases (NDs) have been established, particularly for Alzheimer's disease (AD) and Parkinson's disease (PD). It is unclear why candidate drugs that successfully demonstrate therapeutic effects in animal models fail to show disease-modifying effects in clinical trials. To overcome this hurdle, patients with homogeneous pathologies should be detected as early as possible. The early detection of AD patients using sufficiently tested biomarkers could demonstrate the potential usefulness of combining biomarkers with clinical measures as a diagnostic tool. Cerebrospinal fluid (CSF) biomarkers for NDs are being incorporated in clinical trials designed with the aim of detecting patients earlier, evaluating target engagement, collecting homogeneous patients, facilitating prevention trials, and testing the potential of surrogate markers relative to clinical measures. In this review we summarize the latest information on CSF biomarkers in NDs, particularly AD and PD, and their use in clinical trials. The large number of issues related to CSF biomarker measurements and applications has resulted in relatively few clinical trials on CSF biomarkers being conducted. However, the available CSF biomarker data obtained in clinical trials support the advantages of incorporating CSF biomarkers in clinical trials, even though the data have mostly been obtained in AD trials. We describe the current issues with and ongoing efforts for the use of CSF biomarkers in clinical trials and the plans to harness CSF biomarkers for the development of DMT and clinical routines. This effort requires nationwide, global, and multidisciplinary efforts in academia, industry, and regulatory agencies to facilitate a new era. |
format | Online Article Text |
id | pubmed-5063862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Korean Neurological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-50638622016-10-17 Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges Kim, Dana Kim, Young-Sam Shin, Dong Wun Park, Chang-Shin Kang, Ju-Hee J Clin Neurol Review No disease-modifying therapies (DMT) for neurodegenerative diseases (NDs) have been established, particularly for Alzheimer's disease (AD) and Parkinson's disease (PD). It is unclear why candidate drugs that successfully demonstrate therapeutic effects in animal models fail to show disease-modifying effects in clinical trials. To overcome this hurdle, patients with homogeneous pathologies should be detected as early as possible. The early detection of AD patients using sufficiently tested biomarkers could demonstrate the potential usefulness of combining biomarkers with clinical measures as a diagnostic tool. Cerebrospinal fluid (CSF) biomarkers for NDs are being incorporated in clinical trials designed with the aim of detecting patients earlier, evaluating target engagement, collecting homogeneous patients, facilitating prevention trials, and testing the potential of surrogate markers relative to clinical measures. In this review we summarize the latest information on CSF biomarkers in NDs, particularly AD and PD, and their use in clinical trials. The large number of issues related to CSF biomarker measurements and applications has resulted in relatively few clinical trials on CSF biomarkers being conducted. However, the available CSF biomarker data obtained in clinical trials support the advantages of incorporating CSF biomarkers in clinical trials, even though the data have mostly been obtained in AD trials. We describe the current issues with and ongoing efforts for the use of CSF biomarkers in clinical trials and the plans to harness CSF biomarkers for the development of DMT and clinical routines. This effort requires nationwide, global, and multidisciplinary efforts in academia, industry, and regulatory agencies to facilitate a new era. Korean Neurological Association 2016-10 2016-09-30 /pmc/articles/PMC5063862/ /pubmed/27819412 http://dx.doi.org/10.3988/jcn.2016.12.4.381 Text en Copyright © 2016 Korean Neurological Association http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Kim, Dana Kim, Young-Sam Shin, Dong Wun Park, Chang-Shin Kang, Ju-Hee Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges |
title | Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges |
title_full | Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges |
title_fullStr | Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges |
title_full_unstemmed | Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges |
title_short | Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges |
title_sort | harnessing cerebrospinal fluid biomarkers in clinical trials for treating alzheimer's and parkinson's diseases: potential and challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063862/ https://www.ncbi.nlm.nih.gov/pubmed/27819412 http://dx.doi.org/10.3988/jcn.2016.12.4.381 |
work_keys_str_mv | AT kimdana harnessingcerebrospinalfluidbiomarkersinclinicaltrialsfortreatingalzheimersandparkinsonsdiseasespotentialandchallenges AT kimyoungsam harnessingcerebrospinalfluidbiomarkersinclinicaltrialsfortreatingalzheimersandparkinsonsdiseasespotentialandchallenges AT shindongwun harnessingcerebrospinalfluidbiomarkersinclinicaltrialsfortreatingalzheimersandparkinsonsdiseasespotentialandchallenges AT parkchangshin harnessingcerebrospinalfluidbiomarkersinclinicaltrialsfortreatingalzheimersandparkinsonsdiseasespotentialandchallenges AT kangjuhee harnessingcerebrospinalfluidbiomarkersinclinicaltrialsfortreatingalzheimersandparkinsonsdiseasespotentialandchallenges |